Showing results for "Karyopharm"
business
Baystate Business: Markets and Biotech (Radio)On the Thursday, December 6 edition of Bloomberg Baystate Business we talked with Jurrien Timmer of Fidelity about the markets. Dr. Michael Kauffman, CEO of Karyopharm Therapeutics, talked about their new cancer-fighting therapy technologies. David Chang, the new CEO of Gradifi, talked about his company. Anne Mostue reported on the latest meeting of the state gaming commission. Dr. Ed Kaye, CEO of Stoke Therapeutics, talked about treating rare diseases in children. Finally, we talked with AleDecember 7, 2018
technology
Hematology Conference Could Spur Some of Biotech's OutperformersBluebird Bio Inc. and Global Blood Therapeutics Inc. will be among biotechnology companies in the spotlight this week as doctors and investors flock to Stockholm for presentations at the Congress of European Hematology Association.June 13, 2018
business
Bay State Biotech Report: KaryopharmBloomberg’s Catherine Larkin discusses Karyopharm Therapeutics’ treatment of multiple myeloma. That’s all on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host Anne Mostue discuss the latest in biotech news from the Boston area and across the nation.December 7, 2016
business
The Bloomberg Baystate Business HourBloomberg Boston Bureau Chief Tom Moroney and Radio News Anchor Anne Mostue are joined by top names from local business and finance to medicine and politics, along with Bloomberg reporters covering the latest stories in and around Boston. Bloomberg reporter Brian Sullivan talks about weather and energy prices, Karyopharm CEO Michael Kauffman talks about his efforts to treat blood cancer, and Boston Harbor Islands National Park Superintendent Giles Parker talks about the 300th anniversary of BostSeptember 9, 2016